sorafenib has been researched along with artesunic acid in 6 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (artesunic acid) | Trials (artesunic acid) | Recent Studies (post-2010) (artesunic acid) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,089 | 443 | 1,182 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogaerts, E; Colle, I; Descamps, B; Devisscher, L; Geerts, A; Janssens, S; Lambrecht, BN; Laukens, D; Libbrecht, L; Paridaens, A; Van Steenkiste, C; Van Vlierberghe, H; Vandewynckel, YP; Vanhove, C; Verhelst, X | 1 |
| Bartlett, DL; Choudry, HA; Jeong, SY; Lee, DH; Lee, YJ; Lee, YS; Oh, SC; Park, SH; Park, YS; Yu, J | 1 |
| Dong, H; Jing, W; Jun, X; Min, M; Runpeng, Z; Shuo, L; Yingru, X | 1 |
| Gao, JJ; Wang, K; Yao, X; Yin, H; Zhao, CR | 1 |
| Chen, PH; Dai, HQ; Deng, JH; Feng, J; Huang, XW; Li, ZJ; Liu, YJ; Lu, GD; Shi, H; Wang, JG; Wang, ZX; Wu, Y; Yang, XM; Zhou, J | 1 |
| Chen, Y; Gao, J; He, Z; Jia, Y; Tao, H; Wang, F; Wu, P; Zhang, X; Zhou, Z | 1 |
6 other study(ies) available for sorafenib and artesunic acid
| Article | Year |
|---|---|
Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent.
Topics: Animals; Antineoplastic Agents; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Death; Dose-Response Relationship, Drug; Drug Repositioning; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Unfolded Protein Response | 2014 |
Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Artesunate; Colonic Neoplasms; Drug Synergism; Endoplasmic Reticulum Stress; Female; Ferroptosis; Gene Knockdown Techniques; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Proto-Oncogene Proteins; Receptors, TNF-Related Apoptosis-Inducing Ligand; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor CHOP; Tumor Burden; Tumor Suppressor Protein p53; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Artesunate; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Liver Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Sorafenib; TOR Serine-Threonine Kinases | 2019 |
Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Artesunate; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artesunate; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Ferroptosis; Humans; Lipid Peroxidation; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
Artesunate synergistically promotes sorafenib‑induced apoptosis and ferroptosis in non‑Hodgkin lymphoma cells through inhibition of the STAT3 pathway.
Topics: Apoptosis; Artesunate; Cell Line, Tumor; Ferroptosis; Humans; Lymphoma, Non-Hodgkin; Sorafenib; STAT3 Transcription Factor | 2023 |